journal article·2024-07-05Open access

Challenges and Advances in Magnetic Nanoparticle-Guided Delivery of Cultured Human Corneal Endothelial Cells—A Review

Virginija Vilkelyte, Polly Thompson, Maria Coelho, Małgorzata Woronkowicz, Piotr Skopinski, Harry Roberts

Applied Sciences· Volume 14· Issue 13

Abstract

The cornea relies on a healthy endothelium to maintain transparency, and damage to endothelial cells can result in corneal oedema and vision loss. Current treatments, which often involve the use of donor corneas, face significant limitations due to a shortage of donor tissue. Although human corneal endothelial cells (HCECs) can be cultured and transplanted, their low attachment rates limit the effectiveness of these treatments. In this review, we examined studies that explore the use of magnetic nanoparticles (MNPs) to enhance the attachment of HCECs to the cornea. We evaluated the effectiveness, cell viability, and safety of this approach. Findings indicate that MNPs facilitate the targeted delivery of HCECs under a magnetic field, resulting in improved corneal clarity and reduced oedema in animal models. Cell viability remained high, and no significant safety concerns were identified. MNPs present a promising strategy to enhance HCEC transplantation. However, further research, including ongoing clinical trials, is necessary to confirm the safety and efficacy of this approach before it can be adopted for widespread clinical use.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Corneal surgery and disorders · Corneal Surgery and Treatments · Ocular Surface and Contact Lens

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

University of Exeter Medical School, St Luke’s Campus, University of Exeter, Exeter EX1 2HZ, UK

West of England Eye Unit, Royal Devon University Healthcare NHS Foundation Trust, Exeter EX2 5DW, UK

NDDH, Royal Devon University Healthcare NHS Foundation Trust, Barnstaple EX31 4JB, UK

Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London EC1V 2PD, UK

Department of Ophthalmology, SPKSO Ophthalmic University Hospital, Medical University of Warsaw, 00-576 Warsaw, Poland

Department of Histology and Embryology, Medical University of Warsaw, 02-004 Warsaw, Poland

References (100+)

Show source-provided references
1. Anatomy of cornea and ocular surface10.4103/ijo.IJO_646_17 ↗
2. Anatomy and physiology of the cornea10.1016/j.jcrs.2010.12.037 ↗
3. Human Corneal Anatomy Redefined: A Novel Pre-Descemet’s Layer (Dua’s Layer)10.1016/j.ophtha.2013.01.018 ↗
4. 12. Endothelial pump and barrier function10.1016/j.exer.2020.108068 ↗
5. 3D map of the human corneal endothelial cell10.1038/srep29047 ↗
6. Cell surface markers of functional phenotypic corneal endothelial cells10.1167/iovs.14-14980 ↗
7. Effects of corneal preservation conditions on human corneal endothelial cell culture10.1016/j.exer.2018.11.007 ↗
8. The culture of limbal stromal cells and corneal endothelial cells
9. Cell cycle protein expression and proliferative status in human corneal cells
10. TGF-beta2 in aqueous humor suppresses S-phase entry in cultured corneal endothelial cells
11. Prenatal and postnatal cellularity of the human corneal endothelium. A quantitative histologic study
12. (2024, May 05). Age-Related Changes and Diseases of the Ocular Surface and Cornea |IOVS| ARVO Journals. Available online: https://iovs.arvojournals.org/article.aspx?articleid=2127383.
13. The developing corneal endothelium: Correlation of morphology, hydration and Na/K ATPase pump site density10.3109/02713689109001742 ↗
14. Cellular changes in transplanted human corneas10.1097/00003226-200108000-00002 ↗
15. Proliferative Response of Corneal Endothelial Cells from Young and Older Donors10.1167/iovs.03-0814 ↗
16. Corneal endothelial cell dysfunction: Etiologies and management10.1177/2515841418815802 ↗
17. Risk factors for fluctuations in corneal endothelial cell density (Review)10.3892/etm.2021.11052 ↗
18. Fuchs’ endothelial dystrophy of the cornea10.1016/0039-6257(93)90099-S ↗
19. Posterior polymorphous corneal dystrophy: A disease characterized by epithelial-like endothelial cells which influence management and prognosis
20. Similarities between Posterior Polymorphous and Congenital Hereditary Endothelial Dystrophies: A Study of 14 Buttons of 11 Cases10.1097/00003226-198201020-00011 ↗
21. Progressive essential iris atrophy, Chandler’s syndrome, and the iris nevus (Cogan-Reese) syndrome: A spectrum of disease10.1016/0039-6257(79)90143-7 ↗
22. Effect of silicone elastomer contact lens wear on endothelial cell morphology in aphakic eyes10.1097/00003226-199001000-00009 ↗
23. Estimation of corneal endothelial pump function in long-term contact lens wearers
24. Continued endothelial cell loss ten years after lens implantation10.1016/S0161-6420(94)31224-3 ↗
25. Endothelial Keratoplasty Update 202010.1097/ICO.0000000000002565 ↗
26. Endothelial keratoplasty—A review10.1111/j.1442-9071.2010.02213.x ↗
27. A surgical technique for posterior lamellar keratoplasty10.1097/00003226-199811000-00010 ↗
28. A technique to excise the descemet membrane from a recipient cornea (descemetorhexis)10.1097/00003226-200404000-00011 ↗
29. Global Survey of Corneal Transplantation and Eye Banking10.1001/jamaophthalmol.2015.4776 ↗
30. Descemet’s membrane endothelial keratoplasty (DMEK) versus Descemet’s stripping automated endothelial keratoplasty (DSAEK) for corneal endothelial failure
31. Endothelial keratoplasty: Evolution and horizons10.1590/S0004-27492012000600016 ↗
32. Descemet’s stripping endothelial keratoplasty: Safety and outcomes: A report by the American Academy of Ophthalmology10.1016/j.ophtha.2009.06.021 ↗
33. Ultrathin Descemet Stripping Automated Endothelial Keratoplasty (UT-DSAEK) versus Descemet Membrane Endothelial Keratoplasty (DMEK)—A systematic review and meta-analysis10.1038/s41433-023-02467-2 ↗
34. Perceived difficulties and barriers to uptake of Descemet’s membrane endothelial keratoplasty among surgeons10.2147/OPTH.S212871 ↗
35. Nanotechnology-based strategies for treatment of ocular disease10.1016/j.apsb.2016.09.001 ↗
36. Chaurasia, S.S., Lim, R.R., Lakshminarayanan, R., and Mohan, R.R. (2015). Nanomedicine Approaches for Corneal Diseases. J. Funct. Biomater., 6.10.3390/jfb6020277 ↗
37. Magnetic Characterization of Iron Oxide Nanoparticles for Biomedical Applications10.1007/978-1-4939-6840-4_4 ↗
38. Magnetic Nanoparticles in MR Imaging and Drug Delivery10.1016/j.addr.2008.03.018 ↗
39. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications10.2217/17435889.2.1.23 ↗
40. Magnetic nanoparticle carrier for targeted drug delivery: Perspective, outlook and design10.1179/174328408X341690 ↗
41. Optimization of release from magnetically controlled polymeric drug release devices10.1016/0142-9612(93)90182-2 ↗
42. Raju, H.B., Hu, Y., Vedula, A., Dubovy, S.R., and Goldberg, J.L. (2011). Evaluation of magnetic micro- and nanoparticle toxicity to ocular tissues. PLoS ONE, 6.10.1371/journal.pone.0017452 ↗
43. Magnetic nanoparticles: A strategy to target the choroidal layer in the posterior segment of the eye10.1038/srep43092 ↗
44. Yu, S., Zhang, H., Zhang, S., Zhong, M., and Fan, H. (2021). Ferrite Nanoparticles-Based Reactive Oxygen Species-Mediated Cancer Therapy. Front. Chem., 9.10.3389/fchem.2021.651053 ↗
45. Anti-bacterial and in vivo tumor treatment by reactive oxygen species generated by magnetic nanoparticles10.1039/c3tb20907e ↗
46. Heterogeneous surface architectured pH responsive Metal-Drug Nano-conjugates for mitochondria targeted therapy of Glioblastomas: A multimodal intranasal approach10.1016/j.cej.2020.124419 ↗
47. Pankhurst, Q., Connolly, J., Jones, S., and Dobson, J. (2003). TOPICAL REVIEW: Applications of magnetic nanoparticles in biomedicine. J. Phys. Appl. Phys., 36.10.1088/0022-3727/36/13/201 ↗
48. Magnetofection: Enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields10.1081/LPR-120017486 ↗
49. Bono, N., Ponti, F., Mantovani, D., and Candiani, G. (2020). Non-Viral in Vitro Gene Delivery: It is Now Time to Set the Bar!. Pharmaceutics, 12.10.3390/pharmaceutics12020183 ↗
50. Regenerative Cell Therapy for Corneal Endothelium10.1007/s40135-014-0043-7 ↗
51. Mass culture of human corneal endothelial cells10.1001/archopht.1979.01020010590018 ↗
52. Peh, G.S.L., Toh, K.P., Wu, F.Y., Tan, D.T., and Mehta, J.S. (2011). Cultivation of human corneal endothelial cells isolated from paired donor corneas. PLoS ONE, 6.10.1371/journal.pone.0028310 ↗
53. Phenotypic and functional characterization of corneal endothelial cells during in vitro expansion10.1038/s41598-020-64311-x ↗
54. Propagation of human corneal endothelial cells: A novel dual media approach10.3727/096368913X675719 ↗
55. A Cell Culture Approach to Optimized Human Corneal Endothelial Cell Function10.1167/iovs.17-23637 ↗
56. Effects of ascorbic acid and ascorbic acid 2-phosphate, a long-acting vitamin C derivative, on the proliferation and differentiation of human osteoblast-like cells10.1016/j.cellbi.2004.01.010 ↗
57. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth10.1038/325257a0 ↗
58. Increased proliferation and replicative lifespan of isolated human corneal endothelial cells with L-ascorbic acid 2-phosphate10.1167/iovs.11-7592 ↗
59. Fibroblast growth factor 2 induces proliferation and fibrosis via SNAI1-mediated activation of CDK2 and ZEB1 in corneal endothelium10.1074/jbc.RA117.000295 ↗
60. Regulatory role of FGF-2 on type I collagen expression during endothelial mesenchymal transformation10.1167/iovs.05-0818 ↗
61. Isolation and long-term cultivation of human corneal endothelial cells
62. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor10.1167/iovs.08-2634 ↗
63. Use and properties of ROCK-specific inhibitor Y-2763210.1016/S0076-6879(00)25449-9 ↗
64. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases
65. Effect of Magnetic Microparticles on Cultivated Human Corneal Endothelial Cells10.1167/tvst.12.2.14 ↗
66. Challenges in corneal endothelial cell culture10.2217/rme-2020-0202 ↗
67. Functional Evaluation of Two Corneal Endothelial Cell-Based Therapies: Tissue-Engineered Construct and Cell Injection10.1038/s41598-019-42493-3 ↗
68. Tissue-Engineered Corneal Endothelial Sheets Using Ultrathin Acellular Porcine Corneal Stroma Substrates for Endothelial Keratoplasty10.1021/acsbiomaterials.2c00039 ↗
69. Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy10.1056/NEJMoa1712770 ↗
70. Animal models of corneal endothelial dysfunction to facilitate development of novel therapies10.21037/atm-20-4389 ↗
71. ROCK Inhibitor Converts Corneal Endothelial Cells into a Phenotype Capable of Regenerating In Vivo Endothelial Tissue10.1016/j.ajpath.2012.03.033 ↗
72. Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction10.1038/srep26113 ↗
73. In Vivo Functionality of a Corneal Endothelium Transplanted by Cell-Injection Therapy in a Feline Model10.1167/iovs.15-17625 ↗
74. Magnetic attraction of iron-endocytosed corneal endothelial cells to Descemet’s membrane10.1016/S0014-4835(03)00057-5 ↗
75. Sphere Therapy for Corneal Endothelium Deficiency in a Rabbit Model10.1167/iovs.05-0251 ↗
76. Five-Year Follow-up of First 11 Patients Undergoing Injection of Cultured Corneal Endothelial Cells for Corneal Endothelial Failure10.1016/j.ophtha.2020.09.002 ↗
77. Aurion Biotech (2024, January 01). CLARA: A Phase 1/2 Multi-Center, Randomized, Double-Masked, Prospective, Parallel-Arm Study of AURN001 in Subjects with Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1). 2024; Report No.: NCT06041256, Available online: https://clinicaltrials.gov/study/NCT06041256.
78. RhoA and ROCK Promote Migration by Limiting Membrane Protrusions10.1074/jbc.M211584200 ↗
79. Magnetic Nanoparticles as a Potential Vehicle for Corneal Endothelium Repair10.7205/MILMED-D-15-00151 ↗
80. Magnetic field-guided cell delivery with nanoparticle-loaded human corneal endothelial cells10.1016/j.nano.2014.12.002 ↗
81. Magnetic Human Corneal Endothelial Cell Transplant: Delivery, Retention, and Short-Term Efficacy10.1167/iovs.18-26001 ↗
82. Long-term outcome of iron-endocytosing cultured corneal endothelial cell transplantation with magnetic attraction10.1016/j.exer.2004.08.021 ↗
83. Injectable magnetic hyaluronic acid gel for corneal endothelial cells efficient delivery and retention10.1016/j.apmt.2024.102090 ↗
84. MiRNA 24-3p-rich exosomes functionalized DEGMA-modified hyaluronic acid hydrogels for corneal epithelial healing
85. Supramolecular host-guest hyaluronic acid hydrogels enhance corneal wound healing through dynamic spatiotemporal effects10.1016/j.jtos.2021.09.002 ↗
86. Koivusalo, L., Kauppila, M., Samanta, S., Parihar, V.S., Ilmarinen, T., Miettinen, S., Oommen, O.P., and Skottman, H. (2019). Tissue adhesive hyaluronic acid hydrogels for sutureless stem cell delivery and regeneration of corneal epithelium and stroma. Biomaterials, 225.10.1016/j.biomaterials.2019.119516 ↗
87. Hydrazone crosslinked hyaluronan-based hydrogels for therapeutic delivery of adipose stem cells to treat corneal defects10.1016/j.msec.2017.12.013 ↗
88. Real-time in vivo monitoring of intraocular pressure distribution in the anterior chamber and vitreous chamber for diagnosis of glaucoma10.1126/sciadv.adk7805 ↗
89. Effect of hyaluronic acid on intraocular pressure in rats
90. Emmecell (2024, January 01). A Phase 1, Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Assess the Safety, and Tolerability of EO2002 with and without Endothelial Brushing or Descemet Stripping in the Treatment of Corneal Edema (EMME-001). 2024; Report No.: NCT04894110, Available online: https://clinicaltrials.gov/study/NCT04894110.
91. Asociación para Evitar la Ceguera en México (2024, January 01). Phase 1, Multiple Dose, Open-Label Study to Assess the Safety and Tolerability of EO2002 Intracameral Injections with or without Topical Ripasudil in the Treatment of Corneal Edema. 2022. Report No.: NCT05636579, Available online: https://clinicaltrials.gov/study/NCT05636579.
92. Biocompatibility and Toxicity of Magnetic Nanoparticles in Regenerative Medicine10.1155/2012/614094 ↗
93. Investigation of nanoparticles using magnetic resonance imaging after intravitreal injection10.1111/j.1442-9071.2011.02651.x ↗
94. Silica and titanium dioxide nanoparticles cause pregnancy complications in mice10.1038/nnano.2011.41 ↗
95. Iron oxide nanoparticles induced cytotoxicity, oxidative stress and DNA damage in lymphocytes10.1002/jat.3485 ↗
96. Acute toxicity of nickel nanoparticles in rats after intravenous injection
97. Yang, C., Yang, J., Lu, A., Gong, J., Yang, Y., Lin, X., Li, M., and Xu, H. (2022). Nanoparticles in ocular applications and their potential toxicity. Front. Mol. Biosci., 9.10.3389/fmolb.2022.931759 ↗
98. Exocytosis of nanoparticles from cells: Role in cellular retention and toxicity10.1016/j.cis.2013.10.013 ↗
99. Magnetic Hyperthermia with Magnetic Nanoparticles: A Status Review10.2174/1568026614666140118203550 ↗
100. Temperature Distribution Simulation of the Human Eye Exposed to Laser Radiation